Navigation Links
Celator(R) Pharmaceuticals Study Shows CPX-571 Maintains Synergistic Ratio of Irinotecan and Cisplatin to Improve Anti-tumor Activity
Date:10/26/2007

Promising pre-clinical results support advance to clinical study for third combination chemotherapy from Celator based on the company's proprietary

CombiPlex(TM) technology platform.

PRINCETON, N.J., Oct. 26 /PRNewswire/ -- Celator Pharmaceuticals today announced positive results from preclinical studies to evaluate the optimal ratio of irinotecan and cisplatin to deliver synergistic benefit against a range of tumor cell lines in vitro. The study further worked to develop an effective formulation to maintain the optimal ratio of these drugs in vivo. Results were presented this week in a poster presentation at the AACR-NCI- EORTC International Conference on Molecular Targets and Cancer Therapeutics in San Francisco, CA.

In the study, combinations of irinotecan and cisplatin were applied to a panel of 20 human and murine tumor cell lines enriched with lung tumor carcinomas in vitro to identify the ratios most likely to deliver synergistic benefit. The combination exhibited strong drug ratio dependent synergy. Using Celator's proprietary CombiPlex technology, researchers then engineered a combination of irinotecan and cisplatin in liposomes to maintain a synergistic 7:1 molar ratio following intravenous administration. The product, known as CPX-571, was compared to a combination of irinotecan and cisplatin administered as free drugs, and to monotherapy with each drug agent administered in a liposome formulation in mice implanted with human solid tumor xenografts. In all tumor models tested, CPX-571 showed a high degree of anti-tumor activity and significantly improved efficacy as compared to the combination of free drugs and to the individual liposomal drug agents.

"In this study we were able to identify the optimal ratio of irinotecan and cisplatin to use in combination chemotherapy and then combine the drugs in a formulation able to maintain that ratio in animal models. Along with our progress in developing CPX-1, curre
'/>"/>

SOURCE Celator Pharmaceuticals
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Deltanoid Pharmaceuticals begins phase II osteoporosis study
2. The Coming of Biotech Generic Pharmaceuticals
3. Antibodies for Studying NMDA Receptor Protein Expression and Synapse-Specific Immunolabeling
4. Optimizing Transfection Conditions for Studying Signal Transduction Pathways
5. Enzyme Immunoassay for Studying Intracellular Levels of cAMP
6. RT-PCR Primers for the Study of Apoptosis
7. A Comparison Study of Lipid Tranfection Reagents in A549, NIH 3T3 and COS-7 Cell Lines
8. New Reporter Plasmids for Studying Interferon-Stimulated Signal Transduction Pathways
9. New Fusion Trans-Activator Plasmids for Studying Signal Transduction Pathways
10. Medical College receives $377K to study brain disease
11. Kauffman study shows consistent entrepreneurial growth
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/16/2015)... Mass. , April 16, 2015  In recognition of ... collaborated with hemophilia advocacy groups to illuminate more than 15 ... , including Boston,s Zakim Bridge and ... New Orleans, Mercedes-Benz Superdome and ... occur during the evening of April 17, and coincide with ...
(Date:4/16/2015)... 2015  RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the ... venture with G-treeBNT (ReGenTree LLC) has retained Ora, ... for the orphan disorder, neurotrophic keratopathy (NK), and ... syndrome (DES) in the U.S.  Both trials will ... year.  Each of these eye disorders was being ...
(Date:4/16/2015)... 2015 ChemRar High ... and R&D group, and Lancet, Russian Distribution ... and commercialization of new medicines in ... to stimulate the innovative development of the ... http://photos.prnewswire.com/prnh/20150416/739742-a) ,     (Logo: http://photos.prnewswire.com/prnh/20150416/739742-b) , ...
(Date:4/16/2015)... DIEGO , April 16, 2015  AnaptysBio, ... development of therapeutic antibodies, today announced the ... antibody program into IND-enabling studies. The Company,s ... novel treatment for generalized pustular psoriasis (GPP), ... unmet medical need. ANB019 is wholly owned within ...
Breaking Biology Technology:Biogen Shines A Light On Hemophilia Community By Illuminating U.S. Landmarks Red On World Hemophlia Day 2Biogen Shines A Light On Hemophilia Community By Illuminating U.S. Landmarks Red On World Hemophlia Day 3Biogen Shines A Light On Hemophilia Community By Illuminating U.S. Landmarks Red On World Hemophlia Day 4RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 2RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 3RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 4RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 5Lancet and ChemRar High Tech Center Have Announced a Partnership in the Development and Production of Novel Drugs in Russia 2AnaptysBio Advances First-In-Class Anti-IL-36 Receptor Antibody Program To Treat Orphan Inflammatory Disease 2
... Exosome Diagnostics, a leading developer of biofluid-based ... today announced the appointment of David Okrongly, Ph.D., ... as chief medical officer, and Sally Bowden, Ph.D., ... associate chief of cardiothoracic surgery Harvard University and ...
... -- Boston College researchers have discovered two early-stage phases ... deposition, finding a disorderly tangle of tube growth that ... according to a report in the latest edition of ... thin layer of catalyst, Professor of Physics Zhifeng Ren ...
... October 3, 2011 Agendia, an innovative ... successfully completed a recent, routine inspection of its Irvine, ... (FDA). Agendia received FDA 510(k) clearance for its MammaPrint® ... the first and only test of its kind to ...
Cached Biology Technology:Exosome Diagnostics Announces Additions to Management and Scientific Advisory Board as Company Expands Clinical Validation Studies in Oncology 2Exosome Diagnostics Announces Additions to Management and Scientific Advisory Board as Company Expands Clinical Validation Studies in Oncology 3Exosome Diagnostics Announces Additions to Management and Scientific Advisory Board as Company Expands Clinical Validation Studies in Oncology 4Exosome Diagnostics Announces Additions to Management and Scientific Advisory Board as Company Expands Clinical Validation Studies in Oncology 5Boston College Researchers discover 2 early stages of carbon nanotube growth 2Agendia Successfully Completes Bi-Annual FDA Inspection 2
(Date:3/23/2015)... , March 23, 2015   HOYOS Labs , ... company, today announced that the Company will demonstrate multiple ... enterprise and consumers at Connect:ID on March 23 through ... HOYOS Labs will highlight the IEEE Biometric Open Protocol ... ; and enterprise access control system. BOPS was invented ...
(Date:3/23/2015)... 2015 NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or ... mobile commerce market, announces its biometric payment technology, the Wocket® ... television starting March 30 th . ... New York markets. ... about our new ad campaign following the recent initial shipment ...
(Date:3/20/2015)... , Mar. 19, 2015 Research and Markets ... "Hand Geometry - Global Strategic Business Report" report to ... for Hand Geometry in US$ Thousands. The report provides separate ... Japan , Europe , ... , and Rest of World. Annual estimates and ...
Breaking Biology News(10 mins):HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 2HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 3NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 2NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 3Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 2Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 3Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 4
... Fluctuations in climate can drastically affect the habitability ... UCLA scientists that examined the expansion and contraction of ... UCLA research team, led by assistant professor of atmospheric ... simulation to demonstrate for the first time that the ...
... developed a way to turn memories on and offliterally with ... system that duplicates the neural signals associated with memory, they ... long-term learned behavior, even when the rats had been drugged ... rats remember. Flip it off, and the rats forget," said ...
... the forest, they left a trail of breadcrumbs to ... Global Positioning System (GPS), WiFi, and Bluetooth are the ... colleagues while helping us find our location and map ... devices, with few exceptions, today,s firefighters still rely on ...
Cached Biology News:Ocean's harmful low-oxygen zones growing, are sensitive to small changes in climate 2Ocean's harmful low-oxygen zones growing, are sensitive to small changes in climate 3Restoring memory, repairing damaged brains 2Restoring memory, repairing damaged brains 3Wireless 'breadcrumbs' that won’t become toast when baked...or soggy when hosed 2Wireless 'breadcrumbs' that won’t become toast when baked...or soggy when hosed 3
... Two sizes available for use with 96- or 384-well ... 96 for ease of location on 96-tube plates ... the skirt of the plate* Efficient sealing is ... in conjunction with screw or clip-down hot lid thermal ...
... provides complete components including positive and negative ... fragmentation in cultured cells and tissue sections. ... provides greater sensitivity than biotinylated or digoxigenylated ... cytometry. The kit works well with GFP ...
... Bionic Buffer is a unique ... and TAE (TRIS acetate-EDTA) electrophoresis buffers. ... runs, extremely rapid running times, and ... use in gel electrophoresis after dilution ...
... other fluid sources for 4 vessels while ... each individual pump is controlled electronically. Both, ... maintained. ,High-precision controlled peristaltic pumps can ... allows flow rates between 0.01 to 5 ...
Biology Products: